The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; CureVac; Janssen-Cilag; Merck Sharp & Dohme; Sanofi
Speakers' Bureau - Bayer; MSD
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Janssen-Cilag (Inst)
Clinical experience with PSMA-Actinium-225 (Ac-225) radioligand therapy (RLT) in end-stage metastatic castration-resistant prostate cancer (mCRPC) patients.
 
Maarten Johannes van der Doelen
Research Funding - Bayer (Inst)
 
Niven Mehra
Research Funding - Astellas Pharma (Inst); Janssen-Cilag (Inst)
 
Minke Smits
No Relationships to Disclose
 
Inge M. van Oort
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Janssen-Cilag (Inst); Sanofi (Inst)
 
Marcel J.R. Janssen
No Relationships to Disclose
 
Uwe Haberkorn
Patents, Royalties, Other Intellectual Property - Patent PSMA-617
 
Clemens Kratochwil
No Relationships to Disclose
 
Winald Gerritsen
No Relationships to Disclose